Skip to main content
Clinical Trials/IRCT138706051100N1
IRCT138706051100N1
Completed
Phase 2

?Evaluation of therapeutic efficacy of treatment with olanzapine and halopridol on regional cerebral blood flow measured by SPECT in patients with schizophrenia, correlating with the response to treatment

Deputy of Research, Tehran University of Medical Sciences0 sites28 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Schizopherenia.
Sponsor
Deputy of Research, Tehran University of Medical Sciences
Enrollment
28
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Deputy of Research, Tehran University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • the criteria of DSM\-IV for schizopherenia; neuroleptic drug\-naive or drug\-free for at least 4 weeks; age range from 18\-58 years; filling consent form; no drug tranqulization for at least five half life of the drug; no psychoactive drug therapy for at least 5 half life of the drug. Exclusion criteria: Accompanied disorders of axis 1 or 2 based on DSM\-IV; evidence of neurological disease; History of any drug abuse; elevating hepatic enzymes; pregnancy; thyroid dysfunction; consumption of drugs interferring with HT25 or D2 receptors.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials